What Zai Lab Investors Need to Know

We're taking a closer look at Zai Lab today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 24.0% compared to 1.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:

  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong.

  • Zai Lab has moved -64.3% over the last year compared to -15.5% for the S&P 500 -- a difference of -48.8%

  • ZLAB has an average analyst rating of strong_buy and is -59.07% away from its mean target price of $92.08 per share

  • Its trailing 12 month earnings per share (Eps) is $-5.84

  • Zai Lab has a trailing 12 month Price to Earnings (P/E) ratio of -6.4 while the S&P 500 average is 15.97

  • Its forward earnings per share (Eps) is $-4.62 and its forward P/E ratio is -8.2

  • ZLAB has a Price to Earnings Growth (PEG) ratio of -0.2, which shows the company is fairly valued compared to its earnings.

  • The company has a Price to Book (P/B) ratio of 3.0 in contrast to the S&P 500's average ratio of 2.95

  • Zai Lab is part of the Healthcare sector, which has an average P/E ratio of 13.21 and an average P/B of 4.07

  • Zai Lab has on average reported free cash flows of $-274,577,500.00 over the last four years, during which time they have grown by an an average of -83.0%

  • ZLAB's gross profit margins have averaged -420.0 % over the last four years, during which time they had a growth rate of -519.9 % and a coefficient of variability of 107.4 %.

At Market Interference, our mission is to give investors access to timely and accurate data to help them make better investment decisions. subscribe to our free newsletter today to keep track of each day's market movers!

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.